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Summary
Background Remote Australian Aboriginal communities have among the highest diagnosed rates of sexually 
transmissible infections (STIs) in the world. We did a trial to assess whether continuous improvement strategies 
related to sexual health could reduce infection rates.
Methods In this stepped-wedge, cluster-randomised trial (STIs in remote communities: improved and enhanced 
primary health care [STRIVE]), we recruited primary health-care centres serving Aboriginal communities in remote 
areas of Australia. Communities were eligible to participate if they were classified as very remote, had a population 
predominantly of Aboriginal people, and only had one primary health-care centre serving the population. The health-
care centres were grouped into clusters on the basis of geographical proximity to each other, population size, and 
Aboriginal cultural ties including language connections. Clusters were randomly assigned into three blocks (year 1, 
year 2, and year 3 clusters) using a computer-generated randomisation algorithm, with minimisation to balance 
geographical region, population size, and baseline STI testing level. Each year for 3 years, one block of clusters was 
transitioned into the intervention phase, while those not transitioned continued usual care (control clusters). The 
intervention phase comprised cycles of reviewing clinical data and modifying systems to support improved STI clinical 
practice. All investigators and participants were unmasked to the intervention. Primary endpoints were community 
prevalence and testing coverage in residents aged 16–34 years for Chlamydia trachomatis, Neisseria gonorrhoeae, and 
Trichomonas vaginalis. We used Poisson regression analyses on the final dataset and compared STI prevalences and 
testing coverage between control and intervention clusters. All analyses were by intention to treat and models were 
adjusted for time as an independent covariate in overall analyses. This study was registered with the Australia and New 
Zealand Clinical Trials Registry, ACTRN12610000358044.
Findings Between April, 2010, and April, 2011, we recruited 68 primary care centres and grouped them into 
24 clusters, which were randomly assigned into year 1 clusters (estimated population aged 16–34 years, n=11 286), 
year 2 clusters (n=10 288), or year 3 clusters (n=13 304). One primary health-care centre withdrew from the study 
due to restricted capacity to participate. We detected no difference in the relative prevalence of STIs between 
intervention and control clusters (adjusted relative risk [RR] 0·97, 95% CI 0·84–1·12; p=0·66). However, testing 
coverage was substantially higher in intervention clusters (22%) than in control clusters (16%; RR 1·38; 95% CI 
1·15–1·65; p=0·0006).
Interpretation Our intervention increased STI testing coverage but did not have an effect on prevalence. Additional 
interventions that will provide increased access to both testing and treatment are required to reduce persistently high 
prevalences of STIs in remote communities. 
Funding Australian National Health and Medical Research Council.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license. 
Introduction
The remote communities of central and northern 
Australia are the traditional homelands of Aboriginal 
people, who have lived in such environments for 
over 40 000 years, main taining cultures that are among 
the longest sur viving globally.1 Of approximately 
700 000 Aboriginal people in Australia, an estimated 
20% live in remote and very remote communities. The 
median age of Aboriginal people is younger than the 
non-Indigenous population (20 years vs 36 years) and 
approximately 40% of the population is aged 16–34 years.2
Contact with settlers occurred as recently as the 1980s 
for some com munities.3 A major consequence of contact 
with settlers has been an expanding burden of infectious 
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and non-communicable diseases, which has had a 
profound effect on Aboriginal peoples’ well being and 
livelihoods.4 Sexually transmissible infections (STIs) are 
a particular area of health disadvantage for these 
communities, with the prevalence and incidence of 
Chlamydia trachomatis and Neisseria gonorrhoeae in young 
people among the highest in the world.5,6 Furthermore, 
Trichomonas vaginalis is endemic among women7 and 
Treponema pallidum (syphilis) has resurged after almost 
being eliminated in remote Aboriginal communities and 
has now been declared as a major outbreak spanning 
several Australian jurisdictions.8 These STIs are easily 
detected by accu rate diagnostic tests and curable after 
treatments, both of which are routinely available and 
funded under Australia’s health system. Control 
strategies have therefore been based on the principle of 
test and treat, following local guidelines.9
Primary health-care centres that serve populations in 
remote communities are typically staffed by nurses or 
Aboriginal health practitioners, or both.10 Larger com-
munities might have on-site doctors, but for most 
communities doctors visit periodically. STI control in 
remote communities is a key responsibility of primary 
health care. Clinical guidelines relating to STIs and 
clinicians specially trained in sexual health are available 
to support remote primary health-care clinicians.9 
Despite this support, STI control outcomes such as 
testing rates, follow-up, and management in primary 
health care are far from optimal in these remote 
areas.11,12
One way to enhance and embed STI control efforts in 
primary health care could be via implementation of 
continuous quality improvement strategies. These 
strategies aim to identify and minimise barriers to 
achieving clinical best practice and involve repeated cycles 
of audits and self-assessment, followed by implementation 
and evaluation of system change.13,14 Supported by 
mathematical modelling,15 we hypothe sised that a sexual 
health continuous quality improvement programme 
could substantially reduce community prevalence of STIs 
if coverage of testing and treatment attained sufficiently 
high levels. The STRIVE trial (STIs in remote 
communities: improved and enhanced primary health 
care) was a stepped-wedge, cluster-randomised trial to 
assess the effect of a con tinuous quality improvement 
programme in remote communities of Australia. We have 
previously reported the protocol16 and baseline findings6,17 
and now present the main trial outcomes.
Research in context
Evidence before this study
Before commencing the STRIVE trial, we published a review of 
available literature that had investigated the effect of sexually 
transmissible infection (STI) programmes based on increased 
testing and treatment through primary health-care services in 
remote Aboriginal communities in Australia. We searched 
PubMed, Google Scholar, Infonet, Cochrane Central Register of 
Controlled Trials, and the Australian and New Zealand Clinical 
Trials Registry from database inception until April 30, 2011, 
for publications in English, using variations of the terms 
“Aboriginal”, “programs”, and “STI”.  We also searched 
conference proceedings and bulletins during this period. 
We found four STI programmes in remote communities. The 
programmes that consistently achieved high levels of testing 
coverage, generally through strong and ongoing community 
engagement processes and standardised clinical protocols, 
were able to reduce prevalence of STIs. These findings led us to 
develop a quality improvement intervention that might be 
capable of large-scale sustainable implementation. We also did 
an international review of STI quality improvement 
interventions, and found that two previous trials had been 
done, one in Tanzania and one in Peru, that had investigated 
STI quality improvement strategies on a large scale. These 
trials found an improvement in STI prevalence, but were in 
settings very different to remote Australian communities. 
Additionally, we reviewed the international literature to 
identify methodological strategies for programmes that 
would be a good fit for the remote Australian setting. The 
stepped-wedge design seemed to be the most practical and 
ethical approach for investigating the implementation of a 
large-scale quality improvement strategy for STI control 
because it allowed all participating sites to receive the 
intervention.
Added value of this study
The STRIVE trial was the first large-scale investigation of 
clinical quality improvement strategies for the control of STIs 
in remote Aboriginal community settings. Our quality 
improvement strategies improved testing coverage by 38%, 
across a large number of communities in diverse settings. 
However, this improvement in coverage was not sufficient to 
reduce the community prevalence of infection over the 
timeframe of the study.
Implications of all the available evidence
Because quality improvement strategies are insufficient to 
address the unacceptably high prevalence of STIs in remote 
communities in Australia, the task remains to identify 
additional mechanisms of effective control for these infections. 
New strategies being trialled include the use of point-of-care 
testing and financial incentives for young people to seek 
testing. One jurisdiction in Australia that participated in the 
STRIVE trial has adopted quality improvement as a core 
strategy of its STI control programme in all of its 
government-run clinics that are servicing remote 
communities. Whether longer term or wider use of these 
strategies than discussed here will increase the uptake of 
testing and treatment, and ultimately reduce prevalence of 
STIs, remains to be seen.
Articles
www.thelancet.com/lancetgh   Vol 7   November 2019 e1555
Methods
Study design and clusters
In this stepped-wedge, cluster-randomised trial, we ass-
essed an externally supported, sexual health continuous 
quality improvement programme.16 The programme was 
based on components deemed necessary to control STIs in 
the primary health-care setting and the trial aimed to 
increase testing coverage and timely treatment for 
C trachomatis, N gonorrhoeae, and T vaginalis, consistent 
with clinical guidelines,9 particularly among people aged 
16–24 years who are at the highest risk of STIs. The 
continuous quality improvement programme introduced 
by the trial was supported by four regional trial coordinators, 
who worked in partnership with regional sexual health 
coordinators already in place. The stepped-wedge, cluster-
randomisation design ensured that all participating health 
centres would participate in the continuous quality 
improvement programme during the trial.
We recruited primary health-care centres across 
Australia, and communities were eligible to participate 
if they were classified as very remote according to 
Australian Bureau of Statistics criteria,2 had a population 
of predominantly Aboriginal people, and only had one 
primary health-care centre serving the population. We 
approached the management of health-care centres in 
communities that met eligibility criteria.
STRIVE was approved by the Central Australian Human 
Research Ethics Committee (HREC), the Cairns and 
Hinterland HREC, the HREC of the Northern Territory 
Department of Health and Menzies School of Health 
Research, the University of New South Wales HREC, the 
Western Australian Aboriginal Health Information Ethics 
Committee, and the Western Australian Country Health 
Service Board Research Ethics Committee. Participation 
agreements were signed by all primary health-care centres 
before trial commencement, authorising use of routine 
clinical and laboratory data, under strict conditions of 
confidentiality and de-identification of individuals and 
communities.
Randomisation and masking
After enrolment, the primary-health care centres were 
grouped into 24 clusters on the basis of geographical 
proximity to each other, population size, and Aboriginal 
cultural ties including language connections. Eight of 
24 clusters were randomly assigned to the intervention 
phase by a study statistician (HW) each year during the 
trial (ie, year 1 clusters, year 2 clusters, and year 3 clusters). 
Randomisation was done independently by the trial 
statistician (HW) using a minimisation scheme to balance 
the allocation of the 24 clusters as much as possible with 
respect to geographical region, population size (below and 
above the median), and base line level of STI testing (below 
and above the median).18,19 The allocation of clusters to 
commence the intervention in year 1, 2, or 3 was done 
using a computer-generated randomisation algorithm. 
Primary health-care centres and patients in each cluster 
were not masked to intervention allocation due to the 
nature of the intervention.
Procedures
The continuous quality improvement programme 
intervention has been described in detail previously.16 
Four trial coordinators (BH, BJS, DT-T, JK) supported 
continuous quality improvement activities in partici-
pating primary health-care centres beginning once the 
centre was randomly assigned to commence the 
intervention, with annual visits to each health centre 
by the coordinator, most often accompanied by the 
regional sexual health coordinator. At each annual visit, 
all heath centre staff were invited to participate in 
discussions about the trial. Specifically, they were invited 
to review and discuss their own health centre’s data for 
the preceding year related to the key quantitative 
indicators of sexual health clinical practice as detailed in 
the Outcomes section and to complete an assessment of 
health centre systems in six broad areas as shown in the 
panel. Through group discussion, the staff rated the 
performance of their centre across these six areas on a 
scale of 0 to 11, with 11 indi cating a fully developed system. 
This assessment was to identify strengths and gaps for 
STI control at a health-centre level and address these 
areas as necessary so that changes at the system level 
could be monitored over time. The system assessment 
was adapted from a large-scale primary health-care 
Panel: Components and ideal scenarios of the sexual health 
continuous quality improvement system assessment
Health centre staff rated the performance of their centre 
across the following key areas on a scale of 0 to 11:
• Health hardware: all necessary supplies for the diagnosis 
and treatment of STIs and other sexual-health-related 
conditions are available to clinicians
• Clinical services: the clinic is arranged in a manner that 
facilitates sexual health consultations, including 
assurance of privacy and confidentiality, and gender-
specific clinicians as needed
• Electronic medical records: information is routinely and 
systematically entered in an accessible computerised 
information system
• Health promotion: mechanisms are in place to provide 
education to community members about STIs, their 
prevention and treatment, and the benefits of accessing 
testing
• Organisational commitment to sexual health: sexual health 
is a designated priority area for the health service 
management and clinical staff, with appropriate training, 
protocols, and support
• Surveillance and evaluation: the service regularly collects, 
reviews, and acts on quantitative and qualitative 
information related to its sexual health clinical activities
STIs=sexually-transmissible infections.
Articles
e1556 www.thelancet.com/lancetgh   Vol 7   November 2019
chronic disease continuous quality improvement 
project.13 After the assessment, we invited the health 
centre staff to develop an action plan to improve the 
delivery of sexual health services in the forthcoming year 
on the basis of the data report and outcomes of the 
systems assessment. Trial coordinators also provided 
informal training in sexual health throughout the trial. 
Health centre staff were also provided with reports every 
6 months on STI clinical service activity, followed by a 
meeting to discuss progress against the action plan. 
Coordinators under took follow-up phone calls with each 
health centre at 3 and 9 months during the intervention 
phases and were also available at other times during the 
inter vention phase for additional support. Health centres 
were also offered financial incentives, as previously 
described in our study protocol.16 We used a formula that 
provided payments for achievement of specified clinical 
activities, and funding for small-scale health promotion 
activities to raise awareness of sexual health and STI 
testing in the target population.
Routine practice in all primary health-care centres took 
place according to clinical guidelines that recommend 
offering a test for C trachomatis, N gonorrhoeae, and 
T vaginalis at least once every 12 months for all sexually 
active people aged 16–34 years; testing and treating 
people immediately who present with one or more STI 
syndromes (urethral discharge, genital ulcer, or lower 
abdominal pain in women), or being a contact of 
someone with an STI, or both; offering a repeat test 
2–4 months after treatment for any of these infections; 
and following up named recent sexual contacts to offer 
testing and treatment.9,20,21 All samples collected (urine 
for men and urine or swabs for women depending on 
local guidelines) were sent to nationally accredited diag-
nostic laboratories for routine testing via nucleic acid 
technology. Although not the focus of this trial, primary 
health-care centres also offered syphilis and HIV testing 
as per clinical guidelines.
At baseline, almost all primary health-care centres used 
one of four patient electronic medical record (EMR) 
Figure: Schematic of the STRIVE stepped-wedge, cluster-randomised trial
STRIVE=STI in remote communities: improved and enhanced primary health care.
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Year 1 Year 2 Year 3
Control phase
Transition period to intervention
Intervention phase
Year 1 clusters (n=8) Year 2 clusters (n=8) Year 3 clusters (n=8) Total (n=24)
Population Number tested (%) Population Number tested (%) Population Number tested (%) Population Number tested (%)
16–19 years
Females 1121 280 (25%) 1176 292 (25%) 1362 359 (26%) 3659 921 (25%)
Males 1060 165 (16%) 959 130 (14%) 1278 172 (13%) 3297 467 (14%)
Both sexes 2181 445 (20%) 2135 422 (20%) 2640 531 (20%) 6956 1398 (20%)
20–24 years
Females 1540 429 (28%) 1523 401 (26%) 1869 447 (24%) 4932 1277 (26%)
Males 1315 240 (18%) 1267 193 (15%) 1796 251 (14%) 4378 684 (16%)
Both sexes 2855 669 (23%) 2790 594 (21%) 3665 698 (19%) 9310 1961 (21%)
25–29 years
Females 1741 400 (23%) 1572 329 (21%) 1913 433 (23%) 5226 1162 (22%)
Males 1494 234 (16%) 1309 169 (13%) 1808 195 (11%) 4611 598 (13%)
Both sexes 3235 634 (20%) 2881 498 (17%) 3721 628 (17%) 9837 1760 (18%)
30–34 years
Females 1605 316 (20%) 1348 263 (20%) 1657 311 (19%) 4610 890 (18%)
Males 1410 181 (13%) 1133 135 (12%) 1621 184 (11%) 4164 500 (12%)
Both sexes 3015 497 (16%) 2481 398 (16%) 3278 495 (15%) 8774 1390 (16%)
Total population
Females 6007 1425 (24%) 5619 1285 (23%) 6801 1550 (23%) 18 427 4260 (23%)
Males 5279 820 (16%) 4668 626 (13%) 6503 802 (12%) 16 450 2249 (14%)
Both sexes 11 286 2245 (20%) 10 287 1912 (19%) 13 304 2352 (18%) 34 877 6509 (19%)
Data are n or n (%). Community population were residents aged 16–34 years. Number of people tested is the number tested in the 12 months before the community health 
service joined the trial. STI=sexually transmissible infection. STRIVE=STI in remote communities: improved and enhanced primary health care.
Table 1: Proportion of community population tested for STIs in baseline year in STRIVE community clusters, by age group and sex
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systems. The four EMR systems could provide counts of 
patients seen by time period, Aboriginal status, age, and 
sex, but not by STI control measures relevant to this trial. 
Thereafter, software providers for each EMR system were 
commissioned to develop standardised templates for 
recording test requests, results, symptoms, and treatment 
outcomes to encourage adherence to guidelines and for 
ongoing review of data. All EMR data were provided by all 
primary health-care centres for the period of Jan 1, 2009, 
to Dec 31, 2014. These templates increased completeness 
and consistency of data across primary health-care centres 
and aided in minimising any cluster-level differences in 
data capture, which might have introduced bias into 
results if correlated with study outcomes.
All laboratories serving the participating primary health-
care centres also had computerised systems and provided 
de-identified patient-level data on testing and test results, 
including dates and the age and sex of those tested. These 
records were combined with information from EMR 
systems on the number of individuals and consultations 
to prepare reports on the proportion of com munity 
members who had an STI test (testing coverage), the 
proportion who had a positive result, and the proportion 
of those with a positive result who had a retest 2–4 months 
after the first test as per clinical guidelines.
Completeness of data was assessed regularly for both 
laboratory and clinic data, and we did audits of data 
coding collection procedures if we found a substantial 
discrepancy between laboratory and clinic data.
Outcomes
The primary outcomes, assessed at cluster level, were 
prevalence of C trachomatis, N gonorrhoeae, and 
T vaginalis, or a combination of these, in people aged 
16–34 years, and performance in clinical service activity 
based on the best practice indicators. Prevalence of 
C trachomatis, N gonorrhoeae, and T vaginalis was obtained 
via clinic-based surveys of attendees, using urine samples 
for men, and urine or genital swabs for women, tested 
using nucleic acid technologies. We assessed prevalence 
in each cluster during the pre-intervention period, and 
twice more at 1 year and 2 years after trial commencement. 
We did this assessment by offering STI testing to 
50 females and 50 males aged 16–34 years who attended 
health centres in each of the 24 clusters during the 
designated prevalence periods, unless they had been 
offered testing within the past 3 months. For clusters 
with multiple health centres, the target number of 
100 tests were allocated proportionately to health centres 
by community population size.
The performance of clinical service activity was meas-
ured by the proportion of Aboriginal residents aged 
16–34 years who had at least one test for C trachomatis, 
N gonorrhoeae, and T vaginalis during the year (ie, STI 
testing coverage); the proportion of health service 
patients presenting with STI symptoms during the year 
who received immediate treatment; the proportion of 
Aboriginal residents diagnosed by labo ratory test with 
C trachomatis, N gonorrhoeae, or T vaginalis who were 
treated within 7 days of the test result being received 
from the laboratory; the proportion of patients found by 
laboratory test to have C trachomatis, N gonorrhoeae, or 
T vaginalis who had a test for reinfection 2–4 months 
after diagnosis; and the proportion of named sexual 
contacts of those with a positive test result who were 
Year 1 prevalence survey Year 2 prevalence survey
Number of 
positive 
diagnoses
Number 
tested
Crude 
prevalence
Number of 
positive 
diagnoses
Number 
tested
Crude 
prevalence
Females
Any STI
Control clusters 205 876 23% 96 526 18%
Intervention clusters 82 430 19% 207 967 21%
C trachomatis
Control clusters 73 871 8% 19 526 4%
Intervention clusters 33 428 8% 72 963 8%
N gonorrhoeae
Control clusters 50 870 6% 27 524 5%
Intervention clusters 21 429 5% 52 963 5%
T vaginalis
Control clusters 133 746 18% 73 433 17%
Intervention clusters 59 402 15% 138 921 15%
Males
Any STI
Control clusters 79 494 16% 36 291 12%
Intervention clusters 59 343 17% 98 653 15%
C trachomatis
Control clusters 48 494 10% 17 290 6%
Intervention clusters 26 342 8% 47 653 7%
N gonorrhoeae
Control clusters 38 492 8% 22 291 8%
Intervention clusters 24 343 7% 52 653 8%
T vaginalis
Control clusters 10 368 3% 7 229 3%
Intervention clusters 25 316 8% 25 630 4%
Both sexes
Any STI
Control clusters 284 1370 21% 132 817 16%
Intervention clusters 141 773 18% 305 1620 19%
C trachomatis
Control clusters 121 1365 9% 36 816 4%
Intervention clusters 59 770 8% 119 1616 7%
N gonorrhoeae
Control clusters 88 1362 6% 119 1616 7%
Intervention clusters 45 772 6% 104 1616 6%
T vaginalis
Control clusters 143 1114 13% 80 662 12%
Intervention clusters 84 718 12% 163 1551 10%
Year 1 and 2 are defined in relation to the start of the intervention. STI=sexually transmissible infection. 
Table 2: Crude STI prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis 
detected in the year 1 and year 2 surveys, by cluster phase, STI type, and sex
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followed up, tested, and treated. Data for this endpoint 
were obtained from a combination of laboratory and 
health centre EMR systems.
For STI testing coverage, the community population 
was defined as the average annual number of regular 
patients who had a health-related visit in the each of the 
past 2 years, working back from the date the clinic was 
determined to have entered the trial. This is a standard 
approach in Aboriginal primary health care to account 
for a population that is mobile, with people often staying 
for extended periods in other remote communities.22 
Clinical reports were cross-checked with laboratory 
records to provide a count of the number of individuals 
tested in each calendar period. The other performance 
activity indicators were incon sistently recorded across 
the EMR systems, so could not be accurately analysed 
and are not reported here.
Statistical analysis
We did sample size calculations using the method of 
Hayes and Bennett.23 With an assumed C trachomatis and 
N gonorrhoeae prevalence of 15% in the population aged 
16–34 years, based on a previous review of STI programmes 
in remote communities,24 and an average 65% up-
take for the prevalence surveys in each cluster, 14 clusters 
were required to detect a reduction to 7·5% in the 
prevalence of C trachomatis and N gonorrhoeae prevalence 
in intervention clusters with 80% power, two-sided 
α=0·05, with no adjustments for multiple comparisons, 
and equal numbers of clusters in each group.
We hypothesised that the continuous quality improve-
ment intervention would lead to an improvement in 
STI-related clinical performance and a reduction in 
community prevalence of the STIs under investigation. 
Under the published statistical plan, analyses of the 
primary endpoints16 involved two separate comparisons 
(figure). For prevalence endpoints, the two comparisons 
were based on the prevalence surveys done 1 year and 
2 years after the commencement of the intervention 
(ie, year 1 and year 2 surveys) and adjusted for prevalence 
in the baseline survey. Also, for communities that 
undertook prevalence assessments when they were in 
the control group (eg, year 2 and year 3 clusters), the 
testing count for the prevalence period was subtracted 
from the count for that year and replaced by an estimated 
count for the period based on the corresponding time 
period immediately before the preva lence period to 
avoid overcounting due to the fact the surveys were 
being done. For testing coverage endpoints, two 
comparisons were made to measure relative changes in 
testing: these were year 1 intervention phase clusters 
versus year 2 and year 3 control phase clusters combined, 
and year 1 and year 2 intervention phase clusters 
combined versus year 3 control phase clusters. Both 
comparisons were adjusted for time period as an 
independent variable, including baseline performance 
at the cluster level on the basis of data for the 12 months 
before intervention initiation in the year 1 intervention 
phase clusters, 12–24 months before for the year 2 
intervention clusters, and 24–36 months before for the 
year 3 clusters. To facilitate interpretation, we undertook 
additional analyses that combined the out comes from 
the two separate evaluation timepoints to create an 
overall estimate of effect. All com parisons were based 
on an intention-to-treat approach, so did not account for 
the extent to which interventions were implemented at 
each site. We present results as relative risks (RRs) in all 
analyses of STI coverage and prevalence.
We used STATA 9.4 for randomisation and the 
analyses, using generalised estimating equations under 
a Poisson assumption with clusters as panel variables to 
account for within-cluster and between-cluster variation. 
We assumed an exchangeable variance structure, but 
with robust variances calculated. The trial is registered 
with the Australian and New Zealand Clinical Trials 
Registry, ACTRN12610000358044.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all data in the study and had final responsibility 
for the decision to submit for publication.
Results 
Between April, 2010, and April, 2011, we recruited 
68 primary health-care centres to 24 clusters: 57 were in 
the Northern Territory and were allocated to 18 clusters, 
eight were in Western Australia and were allocated to 
Year 1* Year 2† Overall‡ p value
Females
Any STI 0·87 (0·75–1·00) 1·13 (0·96–1·34) 0·94 (0·83–1·05) 0·26
C trachomatis 0·97 (0·62–1·54) 1·90 (1·12–3·24) 1·24 (0·89–1·73) 0·21
N gonorrhoeae 0·87 (0·35–2·13) 1·05 (0·54–2·01) 0·94 (0·51–1·74) 0·84
T vaginalis 0·86 (0·61–1·20) 0·88 (0·65–1·18) 0·83 (0·66–1·05) 0·13
Males
Any STI 1·09 (0·68–1·73) 1·09 (0·68–1·76) 1·09 (0·77–1·54) 0·64
C trachomatis 0·89 (0·57–1·39) 1·14 (0·58–2·25) 1·03 (0·68–1·58) 0·88
N gonorrhoeae 0·91 (0·37–2·21) 1·02 (0·45–2·33) 0·96 (0·49–1·88) 0·90
T vaginalis 3·07 (1·33–7·09) 1·03 (0·64–1·66) 1·81 (0·99–3·31) 0·054
Both sexes
Any STI 0·92 (0·75–1·12) 1·11 (0·88–1·39) 0·97 (0·84–1·12) 0·66
C trachomatis 0·97 (0·66–1·42) 1·44 (0·89–2·31) 1·15 (0·84–1·58) 0·39
N gonorrhoeae 0·92 (0·41–2·05) 1·00 (0·53–1·91) 0·94 (0·54–1·64) 0·84
T vaginalis 0·92 (0·65–1·31) 0·86 (0·63–1·18) 0·88 (0·68–1·13) 0·31
Data are relative risk, with 95% CIs in parentheses. All comparisons are adjusted for baseline (before intervention) 
prevalence, and a relative risk of >1 indicates a higher STI prevalence in intervention clusters than in control clusters. 
STI=sexually transmissible infection. *Comparing prevalence in year 1 intervention phase clusters with year 2 and 
year 3 control phase clusters. †Comparing prevalences in year 1 and 2 intervention phase clusters with year 3 control 
phase clusters. ‡Comparing prevalence in intervention phase clusters with control phase clusters.
Table 3: Adjusted relative prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas 
vaginalis for the intervention clusters versus control clusters, by sex 
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three clusters, and three communities in Queensland 
were each classified as a cluster. The intervention period 
of the trial ran from September, 2011, to September, 2014. 
Over 70% (n=48) of participating primary health-care 
centres were government run and the remainder were 
governed by local Aboriginal people—known as 
Aboriginal com munity-controlled services. 25 The median 
number of staff per health centre was 5·5 full-time 
equivalent.  15 (22%) health centres had 50% or more of 
their clinical staff employed for less than 12 months 
before trial commencement.
All 24 clusters were included in all assessments with 
only one health-care centre with drawing before starting 
the intervention because of restricted capacity to 
participate; no data from this centre were used. The 
conservative sample size estimation was robust to this 
withdrawal and the study was powered to estimate the 
outcomes despite this event.
The baseline population of individuals aged 16–34 years 
were similar in size across all clusters, comprising 
11 286 people in the year 1 clusters, 10 288 people in 
the year 2 clusters, and 13 304 in the year 3 clusters. The 
mean ages were similar, at 25·2 years (SD 5·4) for the 
year 1 clusters, 24·9 years (SD 5·4) for the year 2 clusters, 
and 25·0 years (SD 5·4) for the year 3 clusters. Women 
comprised over half of regular patients in all three cluster 
groups, at 53% (n=6007) in the year 1 clusters, 55% 
(n=5619) in the year 2 clusters, and 51% (n=6801) in the 
year 3 clusters.
Community testing coverage for STIs (each of 
C trachomatis, N gonorrhoeae, and T vaginalis) in the 
baseline year was slightly higher at 20% in the year 1 
intervention phase clusters, than the 19% coverage in the 
year 2 and the 18% coverage in year 3 control phase 
clusters. Among males, baseline testing coverage was 
much lower across all age groups and all clusters than 
among females, with an overall 14% of males tested 
compared with 23% of females (table 1).
Three rounds of prevalence assessments (baseline, 
year 1, and year 2 surveys) were completed at all sites, as 
were 270 systems assessment visits by trial coordinators, 
and a further 340 contacts for 6-month follow-ups. During 
the three prevalence assessments, 2292 patients were 
tested for STIs at baseline, 2143 in the year 1 survey, and 
2437 in the year 2 survey. More than half of all patients 
tested were women: 56% at baseline, 61% in year 1, and 
61% in year 2 (table 2). Crude prevalences of STIs at year 1 
and year 2 differed little between intervention and control 
clusters (table 3). N gonorrhoeae and C trachomatis 
were detected at similar prevalences between control 
and intervention clusters and differed little by sex. For 
example, in the year 1 prevalence survey, the proportion 
of females with C trachomatis was 8% in both the control 
and intervention clusters, and in males it was 10% in 
the intervention clusters and 8% in the control clusters. 
In females the crude prevalence of T vaginalis was 
approximately twice the prevalence of N gonorrhoeae and 
C trachomatis, and in males it was approximately half 
the prevalence of N gonorrhoeae and C trachomatis, apart 
from among males in the intervention clusters at the year 1 
prevalence survey, for whom the prevalence of T vaginalis 
was similar to the prevalence of N gonorrhoeae and 
C trachomatis.
Year 1 Year 2
Number 
tested
Estimated 
resident 
population
Coverage Number 
tested
Estimated 
resident 
population
Coverage
Females
Any STI
Control clusters 2684 12 420 22% 1332 6801 20%
Intervention clusters 1628 6007 27% 2999 11626 26%
C trachomatis
Control clusters 3042 12 420 25% 1701 6801 25%
Intervention clusters 1782 6007 30% 3182 11626 27%
N gonorrhoeae
Control clusters 3037 12 420 25% 1697 6801 25%
Intervention clusters 1781 6007 30% 3181 11 626 27%
T vaginalis
Control clusters 2691 12 420 22% 1332 6801 20%
Intervention clusters 1632 6007 27% 3000 11 626 26%
Males
Any STI
Control clusters 1339 11 171 12% 530 6503 8%
Intervention clusters 1109 5279 21% 1551 9947 16%
C trachomatis
Control clusters 1555 11 171 14% 737 6503 11%
Intervention clusters 1214 5279 23% 1671 9947 17%
N gonorrhoeae
Control clusters 1553 11 171 14% 736 6503 11%
Intervention clusters 1209 5279 23% 1668 9947 17%
T vaginalis
Control clusters 1344 11 171 12% 531 6503 8%
Intervention clusters 1112 5279 21% 1554 9947 16%
Both sexes
Any STI
Control clusters 4023 23 591 17% 1862 13 304 14%
Intervention clusters 2737 11 286 24% 4550 21 573 21%
C trachomatis
Control clusters 4597 23 591 19% 2438 13 304 18%
Intervention clusters 2996 11 286 26% 4853 21 573 22%
N gonorrhoeae
Control clusters 4590 23 591 19% 2433 13 304 18%
Intervention clusters 2990 11 286 26% 4849 21 573 22%
T vaginalis
Control clusters 4035 23 591 17% 1863 13 304 14%
Intervention clusters 2744 11 286 24% 4554 21 573 21%
Year 1 and 2 are defined for each cluster in relation to the time when it commenced involvement in the trial. Coverage 
is calculated as the crude ratio of number of individuals tested in the period divided by the estimated resident 
population at baseline. STI=sexually transmissible infection.
Table 4: Crude STI testing coverage for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas 
vaginalis in intervention years 1 and 2, by cluster phase, STI type, and sex
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In the corresponding adjusted analyses (table 3), taking 
into account baseline prevalence, the overall relative risk 
comparing interven tion clusters and control clusters was 
0·97 (95% CI 0·84–1·12). The prevalence did not 
significantly differ between intervention and control 
clus ters for males or females overall, or for any of the 
individual STIs.
Testing coverage varied substantially by sex, STI, and 
intervention phase. Crude coverage (table 4) of testing for 
all of three STIs in year 1 was 24% in intervention clusters 
compared with 17% in control clusters, and 21% for the 
intervention and 14% for the control clusters in year 2, 
giving an overall crude coverage of 22% in intervention 
clusters compared with 16% in control clusters. The 
difference in crude coverage between intervention and 
control clusters was more pronounced for males than for 
females—eg, in year 1, male testing coverage was 21% in 
intervention clusters compared with 12% in control 
clusters, whereas for females testing coverage was 27% in 
intervention clusters and 22% in control clusters. The 
differences between intervention and control clusters in 
crude coverage were generally also greater for T vaginalis 
testing, particularly for males, than for N gonorrhoeae and 
C trachomatis.
In the adjusted STI coverage analyses (table 5), 
accounting for baseline testing and time periods, 
the overall coverage of testing was 38% (RR 1·38, 95% CI 
1·15–1·65; p=0·0006) higher in intervention clusters, with 
rela tive increases of 26% (1·26, 1·08–1·48; p=0·0035) in 
females and 62% (1·62; 1·23–2·14; p=0·0006) in males. 
The biggest relative increases were for T vaginalis testing, 
in both males and females. The absolute difference of STI 
testing coverage was 6% in the proportion comprehensively 
tested (95% CI 2–9; p=0·001), and among males it was 7% 
(3–12; p<0·001) compared with 5% among females (1–8; 
p=0·006; appendix p 1).
Discussion
After implementation of a continuous quality improve-
ment programme for STIs, we did not detect any 
reduction in STI prevalence despite significant increases 
in testing among both females and males. The increase 
in STI testing coverage was substantial, overall (38%) 
and among males (61% at year 1, 83% at year 2, and 62% 
overall) across all three infections. In females the 
difference in testing coverage was substantially smaller 
(23% at year 1, 35% at year 2, and 26% overall) and 
driven largely by the increase in testing coverage for 
T vaginalis.
The premise of the continuous quality improvement 
intervention was that health centres in remote com-
munities had qualified clinical staff, diagnostic services, 
and curative drugs for the three STIs of interest, and 
most people at risk attended a centre at least once a year.26 
Therefore, if an intervention could reduce barriers to STI 
testing and management it should lead to an increase 
in the performance of these activities. The continuous 
quality improvement strategies inves tigated by STRIVE 
achieved this goal as shown here by the increase in STI 
testing coverage, but not to a great enough extent to 
reduce STI prevalence.
The absence of effect of the continuous quality 
improvement intervention on the prevalence of infection 
could be due to several reasons. One major issue is that, 
at baseline, the proportion of the target population who 
had at least one STI test in a year was low (23% in females, 
14% in males), so although an increase of 38% overall 
(26% in females and 62% in males), adjusted for baseline 
coverage, in the study population is impressive in relative 
terms, it only translates to absolute increases of 
6–9 percentage points. Previous modelling suggests that 
a relative increase of 200% in testing to attain an 
80% testing coverage would be needed to achieve a 
sustainable decrease in prevalence.17 The discrepancy in 
testing between males and females requires further study 
to identify strategies to improve access to primary health-
care centres and STI testing among males.
Our findings are not dissimilar to those from other 
cluster-randomised controlled trials that aimed to 
improve STI testing in high prevalence settings and that 
have also not shown a reduction in the prevalence of 
infection despite substantial increases in testing.27,28 
Although screening might be an important part of STI 
control, particularly for STIs with a long duration of 
untreated infection due to little recognition of symp-
toms—eg, T vaginalis in women—the early presentation 
of symptomatic individuals might also be critical, 
particu larly for gonorrhoea, which is symptomatic in up 
to 90% of male urethral infections and generally 
See Online for appendix
Year 1* Year 2† Overall‡ p value
Females
Any STI 1·23 (1·06–1·43) 1·35 (1·05–1·75) 1·26 (1·08–1·48) 0·0035
C trachomatis 1·18 (1·07–1·29) 1·07 (0·90–1·26) 1·12 (1·02–1·24) 0·023
N gonorrhoeae 1·18 (1·07–1·30) 1·07 (0·91–1·26) 1·12 (1·02–1·24) 0·019
T vaginalis 1·23 (1·06–1·43) 1·35 (1·05–1·75) 1·26 (1·08–1·47) 0·0036
Males
Any STI 1·61 (1·12–2·32) 1·83 (1·23–2·71) 1·62 (1·23–2·14) 0·0006
C trachomatis 1·50 (1·11–2·01) 1·36 (1·07–1·73) 1·41 (1·17–1·71) 0·0003
N gonorrhoeae 1·49 (1·11–2·01) 1·36 (1·07–1·73) 1·41 (1·17–1·70) 0·0004
T vaginalis 1·61 (1·12–2·31) 1·83 (1·23–2·71) 1·62 (1·23–2·14) 0·0006
Both sexes
Any STI 1·35 (1·11–1·64) 1·50 (1·12–2·01) 1·38 (1·15–1·65) 0·0006
C trachomatis 1·27 (1·11–1·46) 1·16 (0·97–1·38) 1·22 (1·09–1·36) 0·0004
N gonorrhoeae 1·27 (1·11–1·46) 1·16 (0·98–1·38) 1·22 (1·09–1·36) 0·0004
T vaginalis 1·35 (1·11–1·64) 1·50 (1·12–2·01) 1·38 (1·15–1·65) 0·0006
Data are relative risk, with 95% CIs in parentheses. All comparisons are adjusted for baseline (ie, before intervention) 
testing rate, and a relative risk of >1 indicates higher testing coverage in intervention clusters than control clusters. 
STI=sexually transmissible infection. *Comparing testing coverage in year 1 intervention phase clusters with year 2 and 
year 3 control phase clusters. †Comparing testing in year 1 and 2 intervention phase clusters with year 3 control phase 
clusters. ‡Comparing coverage in intervention phase with control phase clusters. 
Table 5: Adjusted relative testing coverage for Chlamydia trachomatis, Neisseria gonorrhoeae, and 
Trichomonas vaginalis in the intervention phase versus control phase clusters, by sex
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uncommon in populations with high levels of access to 
health care. In remote communities of Australia, 
presentation with symptoms might be delayed due to 
barriers in accessing health services or stigma about 
STIs. Future efforts in STI control might require 
interventions to increase both screening and attendance 
of symptom atic individuals.
An additional issue is that our choice of population age 
group of 16–34 years might have been too broad and that 
an increased shift in community prevalence might have 
been achieved if efforts had been concentrated in those 
aged 16–24 years, for whom prevalences of N gonorrhoeae 
and C trachomatis are particularly high in this setting.6,17,29
The barriers to STI testing in remote communities are 
enduring and well documented and include prioritisation 
by clinicians of other urgent health concerns,30 very high 
levels of turnover of all clinical staff,31 a lack of familiarity 
with STI protocols, clinical settings that do not feel 
welcoming for Aboriginal people to engage on a topic that 
is highly personal and sensitive, and a cross-cultural 
environment in which clinician gender is particularly 
relevant to health-centre patients.30 Furthermore, health 
literacy of remote community residents in relation to 
STIs is lower than for other Australians.32 Ongoing 
advocacy is required to address these issues, because 
comprehensive solutions are unlikely to be achieved at 
the individual health centre level.
Conversely, the fact that the intervention led to 
increases in testing, albeit to less of an extent than was 
required for a reduction in STI prevalence, could also be 
viewed as an indication of the potential for improvement 
in testing coverage and other indicators of clinical 
practice. In-depth interviews with clinicians from 
participating sites have shown that aspects of the con-
tinuous quality improvement programme were highly 
valued and integrated and normalised into routine 
clinical care.33 These aspects included the regular 
clinical data reports, sexual health action plans, and 
systems asses sment discussions with clinical staff. 
Other aspects associated with the continuous quality 
improvement programme, such as financial incentives, 
almost certainly added little value to the programme, 
because they represented a negligible proportion of 
clinic operating budgets and the health promotion 
grants were not viewed as influential by clinicians and 
centre staff in driving the increase in testing.33
Although the continuous quality improvement inter-
vention did not influence one of the primary outcomes of 
the trial, it has led to other favourable outcomes. First, the 
trial was deliberately set up in a manner intended to be 
as pragmatic as possible, regarding both the nature of the 
intervention and the extent to which its processes were 
based on the existing clinical structures and context of 
remote primary health care. Specifically, the trial has 
resulted in the adoption of more standardised approaches 
to testing and treatment protocols and templates for 
recording clinical encounters within EMR systems, 
which were not available to clinicians at the beginning of 
the trial. Data were collected in the trial from both routine 
clinical and laboratory records with no additional 
workload for health centre staff.
This study has also generated evidence about the 
importance of  tracking the numbers of people tested as 
a programmatic indicator, for both community coverage 
and as a denominator against which information on the 
number of infections can be interpreted. This study has 
also provided information on the prevalence of STIs 
across remote communities, including estimates of the 
incidence of STIs,6 and co-infections,17 which before the 
trial were not available
Another benefit of this study is that continuous quality 
improvement methods developed for STRIVE have 
been embedded as a central element of the STI control 
programme within the Northern Territory Government 
clinics across 70 remote communities.34 The goal 
remains to maximise access to testing and treatment for 
individuals, and ultimately to decrease prevalence.
This study had several limitations. First, our data 
collection systems, which were custom built across 
multiple EMRs, meant we did not have independent 
verification of the completeness or accuracy of data on 
clinic attendance and STI testing and treatment. Hence, 
data quality might have differed between control and 
intervention periods, thereby introducing bias, but we 
have no way to determine the extent or direction of any 
bias. The quality of information about treatment and 
partner notification was too low to report here due to 
inconsistent recording of this information or not being 
able to capture the data because it was recorded as text in 
the EMR systems. Better information on treatment, its 
timeliness, and partner testing and treatment will com-
plement the comprehensive data that we have compiled on 
testing. Ongoing work is underway to improve methods to 
capture such data across multiple EMR systems. Another 
methodological weakness was the way that the prevalence 
surveys were run. One problem was that we were not able 
to fund extra staff at the participating clinics or put other 
measures in place to ensure that a high level of participation 
could be achieved during the prevalence survey period. 
Additionally, the extra testing that took place during the 
prevalence survey might have reduced the difference in 
testing created by the intervention. For instance, over 
50% of the testing in control cluster populations took place 
because of the prevalence surveys (data not shown), so we 
adjusted these counts using testing rates from adjacent 
time periods to estimate the number of tests that would 
have taken place had no prevalence asses sment occurred. 
Despite the limitations of our data collection system, an 
alternative means of collecting truly representative data on 
prevalence in studies of this kind was not apparent. 
Household-type surveys in this setting would not have 
been feasible both logistically and financially and testing 
without returning results would have been ethically 
unacceptable. Another methodo logical weakness might 
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have been the definition we used for a regular patient, 
which could have resulted in an undercount of community 
members, particularly among males because they are 
infrequent clinic attendees.35
A few other limitations include that testing coverage 
estimates might be underesti mated because we have 
taken all people in the age group as the denominator, 
whereas the small minority (up to 15%) who are not 
sexually active would not require testing. Furthermore, we 
were unable to distinguish what proportion of 
undertesting was because of patient refusal, but we believe 
on the basis of qualitative data that the gap is primarily 
related to the lack of offer by the clinicians because of 
competing priorities, inexperience, or other factors.
In conclusion, STRIVE has shown that a continuous 
quality improvement programme for STIs can lead to 
improved STI testing, but the challenge of reducing 
unacceptably high prevalences of STIs in remote 
communities remains. Our study has shown that 
continuous quality improvement strategies will need to 
be intensified and sustained over time if they are to 
affect STI community prevalence and ideally be imple-
mented alongside other STI control strategies.
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